Author

Francisco H. Cruzalegui

Observed names: Cruzalegui, F., Cruzalegui, Francisco (Louvain Univ. Catholique, Louvain-la-Neuve (Belgium).), F Cruzalegui, F H Cruzalegui, F. Cruzalegui, F. H. Cruzalegui, FRANCISCO CRUZALEGUI, Francisco Cruzalegui, Francisco H Cruzalegui

Observed institutions: AstraZeneca (United Kingdom), University of Nottingham, Inserm, MRC Laboratory of Molecular Biology, Baylor College of Medicine, Duke Medical Center, Servier (France), Pierre Fabre (France), Institut National de la Recherche Agronomique, Instituto de Medicina Tropical Alexander von Humboldt, Institut de Recherches Internationales Servier (France), Institut de Recherche Pierre Fabre (France), Institut Curie, Medical Research Council

OpenAlex ID: A5074833042

Calmodulin-dependent protein kinase II mediates inactivation of MPF and CSF upon fertilization of Xenopus eggs

1993 · Thierry Lorca, Francisco H. Cruzalegui, et al. · Nature · 449

The p38 and ERK MAP kinase pathways cooperate to activate Ternary Complex Factors and c‐fos transcription in response to UV light.

1996 · M. A. Price, F. H. Cruzalegui, et al. · The EMBO Journal · 335

Control of Recruitment and Transcription-Activating Function of CBP Determines Gene Regulation by NMDA Receptors and L-Type Calcium Channels

1999 · Giles E. Hardingham, Sangeeta Chawla, et al. · Neuron · 280

PDF

Src kinase phosphorylates vascular endothelial-cadherin in response to vascular endothelial growth factor: identification of tyrosine 685 as the unique target site

2006 · Y Wallez, F Cand, et al. · Oncogene · 240

Frequent PTEN genomic alterations and activated phosphatidylinositol 3-kinase pathway in basal-like breast cancer cells

2008 · Bérengère Marty, Virginie Maire, et al. · Breast Cancer Research · 225

PDF

Polo-like Kinase 1: A Potential Therapeutic Option in Combination with Conventional Chemotherapy for the Management of Patients with Triple-Negative Breast Cancer

2012 · Virginie Maire, Fariba Némati, et al. · Cancer Research · 201

ERK activation induces phosphorylation of Elk-1 at multiple S/T-P motifs to high stoichiometry

1999 · Francisco H Cruzalegui, Eva Cano, et al. · Oncogene · 192

TTK/hMPS1 Is an Attractive Therapeutic Target for Triple-Negative Breast Cancer

2013 · Virginie Maire, Céline Baldeyron, et al. · PLoS ONE · 180

PDF

A Novel Ca2+/Calmodulin-Dependent Protein Kinase and a Male Germ Cell-Specific Calmodulin-Binding Protein Are Derived from the Same Gene

1991 · A R Means, F Cruzalegui, et al. · Molecular and Cellular Biology · 147

Mechanisms controlling gene expression by nuclear calcium signals

1998 · Giles E. Hardingham, Francisco H. Cruzalegui, et al. · Cell Calcium · 133

Defining actionable mutations for oncology therapeutic development

2016 · T. Hedley Carr, Robert McEwen, et al. · Nature reviews. Cancer · 132

Biochemical characterization of the multifunctional Ca2+/calmodulin-dependent protein kinase type IV expressed in insect cells.

1993 · F H Cruzalegui, A R Means · Journal of Biological Chemistry · 125

Sensitivity to PI3K and AKT inhibitors is mediated by divergent molecular mechanisms in subtypes of DLBCL

2017 · Tabea Erdmann, Pavel Klener, et al. · Blood · 106

PDF

Transcriptome Analysis of Wnt3a-Treated Triple-Negative Breast Cancer Cells

2015 · Sylvie Maubant, Bruno Tesson, et al. · PLoS ONE · 106

PDF

S49076 Is a Novel Kinase Inhibitor of MET, AXL, and FGFR with Strong Preclinical Activity Alone and in Association with Bevacizumab

2013 · Mike F. Burbridge, Céline J. Bossard, et al. · Molecular Cancer Therapeutics · 95

c‐Jun functions as a calcium‐regulated transcriptional activator in the absence of JNK/SAPK1 activation

1999 · Francisco H. Cruzalegui, Giles E. Hardingham, et al. · The EMBO Journal · 79

Regulation of intrasteric inhibition of the multifunctional calcium/calmodulin-dependent protein kinase.

1992 · F H Cruzalegui, M S Kapiloff, et al. · Proceedings of the National Academy of Sciences · 76

Synthesis and pharmacological evaluation of thieno[2,3-b]pyridine derivatives as novel c-Src inhibitors

2011 · Isabelle Pevet, Cédric Brulé, et al. · Bioorganic & Medicinal Chemistry · 70

Src family tyrosine kinases-driven colon cancer cell invasion is induced by Csk membrane delocalization

2009 · A Sirvent, C Bénistant, et al. · Oncogene · 70

Calcium-regulated protein kinase cascades and their transcription factor targets

2000 · F. H. Cruzalegui, H. Bading* · Cellular and Molecular Life Sciences · 65

Functional significance of co-occurring mutations in PIK3CA and MAP3K1 in breast cancer

2018 · Alvaro Avivar-Valderas, Robert McEwen, et al. · Oncotarget · 50

PDF

Fragment-Derived Selective Inhibitors of Dual-Specificity Kinases DYRK1A and DYRK1B

2021 · David Lee Walmsley, James B. Murray, et al. · Journal of Medicinal Chemistry · 48

Specific Oncogenic Activity of the Src-Family Tyrosine Kinase c-Yes in Colon Carcinoma Cells

2011 · Florence Sancier, Aurélie Dumont, et al. · PLoS ONE · 44

PDF

Intermittent High-Dose Scheduling of AZD8835, a Novel Selective Inhibitor of PI3Kα and PI3Kδ, Demonstrates Treatment Strategies for PIK3CA -Dependent Breast Cancers

2016 · Kevin Hudson, Urs J. Hancox, et al. · Molecular Cancer Therapeutics · 41

PDF

Structure-Guided Discovery of Potent and Selective DYRK1A Inhibitors

2021 · Csaba Weber, Melinda Sipos, et al. · Journal of Medicinal Chemistry · 39

Works count: 126

Citation count: 3,866

H-index: 29

I10-index: 36